Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338052 · ClinicalTrials.gov registry record · Phase 2
Study of Bleeding With Extended Administration of an Oral Contraceptive
A Phase 2 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
NCT00338052 is a Phase 2 study that has completed, run by Warner Chilcott. The registered enrollment target is 207 participants.
The verdict
NCT00338052, a Phase 2 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
Study Summary
This is an non-comparative study. There is no statistical hypothesis. The effects of extension of treatment on bleeding will be recorded and described.
Interventions
- DRUG Norethindrone 1 mg / ethinyl estradiol 20 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00338052
The ClinicalTrials.gov registry entry for NCT00338052 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Norethindrone 1 mg / ethinyl estradiol 20 mcg is the first listed.
NCT00338052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00338052 about?
NCT00338052 is a clinical study titled "Study of Bleeding With Extended Administration of an Oral Contraceptive". This is an non-comparative study. There is no statistical hypothesis. The effects of extension of treatment on bleeding will be recorded and described.
What is the current status of trial NCT00338052?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2006-06. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00338052?
The interventions under investigation include: Norethindrone 1 mg / ethinyl estradiol 20 mcg (DRUG).
Who is sponsoring clinical trial NCT00338052?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.